TY - JOUR
T1 - Theophylline, pentostatin (Nipent), and chlorambucil
T2 - A dose-escalation study targeting intrinsic biologic resistance mechanisms in patients with relapsed lymphoproliferative disorders
AU - Byrd, J. C.
AU - Grever, M. R.
AU - Waselenko, J. K.
AU - Willis, C. R.
AU - Park, K.
AU - Goodrich, A.
AU - Lucas, M. A.
AU - Shinn, C.
AU - Flinn, I. W.
PY - 2000/7/12
Y1 - 2000/7/12
N2 - In spite of the chemosensitivity seen with the initial treatment of malignant lymphoid disorders, relapse is common and death most often occurs as a result of disease progression. This is related to a multitude of resistance mechanisms associated with the various lymphoproliferative disorders. As a result, therapies targeting intrinsic drug-resistance mechanisms are evolving and have become an active area of research. In vitro studies of human chronic lymphocytic leukemia cells incubated with theophylline, a phosphodiesterase inhibitor, resulted in downregulation of bcl-2 concomitant with induction of apoptosis. We describe the preclinical basis for a novel combination therapy involving pentostatin (Nipent; SuperGen, San Ramon, CA), chlorambucil, and theophylline in the treatment of patients with relapsed chronic lymphoproliferative disorders. An ongoing study based on such justification, which is currently accruing patients, is also described. Results from this trial appear promising, and a phase II study is now being planned. Copyright (C) 2000 by W.B. Saunders Company.
AB - In spite of the chemosensitivity seen with the initial treatment of malignant lymphoid disorders, relapse is common and death most often occurs as a result of disease progression. This is related to a multitude of resistance mechanisms associated with the various lymphoproliferative disorders. As a result, therapies targeting intrinsic drug-resistance mechanisms are evolving and have become an active area of research. In vitro studies of human chronic lymphocytic leukemia cells incubated with theophylline, a phosphodiesterase inhibitor, resulted in downregulation of bcl-2 concomitant with induction of apoptosis. We describe the preclinical basis for a novel combination therapy involving pentostatin (Nipent; SuperGen, San Ramon, CA), chlorambucil, and theophylline in the treatment of patients with relapsed chronic lymphoproliferative disorders. An ongoing study based on such justification, which is currently accruing patients, is also described. Results from this trial appear promising, and a phase II study is now being planned. Copyright (C) 2000 by W.B. Saunders Company.
UR - http://www.scopus.com/inward/record.url?scp=0033930783&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0033930783&partnerID=8YFLogxK
M3 - Article
C2 - 10877050
AN - SCOPUS:0033930783
SN - 0093-7754
VL - 27
SP - 37
EP - 40
JO - Seminars in oncology
JF - Seminars in oncology
IS - 3 SUPPL. 5
ER -